Pfizer Should Expand Maraviroc Postmarketing Safety Plans – Cmte.
Executive Summary
Pfizer should conduct wide-ranging postmarketing studies to gather additional safety information on its CCR5 co-receptor antagonist maraviroc, FDA's Antiviral Drugs Advisory Committee recommended
You may also be interested in...
Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August
Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist
Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August
Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist
Merck Isentress advisory committee
Merck's HIV integrase inhibitor Isentress (raltegravir) will be the second potentially first-in-class HIV drug to be reviewed by FDA's Antiviral Drugs Advisory Committee in 2007. The panel will meet Sept. 5 to discuss Merck's treatment claim for use in combination with other antiretroviral agents in treatment-experienced patients with evidence of viral replication despite ongoing therapy. The panel's first meeting of 2007 was held in April to review Pfizer's CCR5 antagonist maraviroc (1"The Pink Sheet" April 30, 2007, p. 24). The committee will meet in closed session Sept. 6...